Weight: Under 11 pounds (mini), 16–32 pounds (standard) ...

BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter ...

In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s ...

Despite formidable competition in the growing transthyretin amyloid cardiomyopathy (ATTR-CM) market, a strong early launch ...

Metabolic syndrome is associated with increased risk for early-onset all-cause dementia, Alzheimer’s disease, and vascular ...

Vietnamese and US descendants of those exposed to Agent Orange continue to face diseases and congenital anomalies.

UK MHRA grants marketing approval for BridgeBio Pharma’s Beyonttra to treat ATTR-CM: Palo Alto, California Wednesday, April 30, 2025, 16:00 Hrs [IST] BridgeBio Pharma, Inc., a n ...

And many people with the condition are cared for at home.

Good afternoon and thank you for joining BridgeBio's Q1 2025 Earnings Conference Call. This is Chinmay Shukla, VP of Strategic Finance at BridgeBio. Today, we will discuss our financial results for ...

U.S. Attruby net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for ...

Scientists using living human brain tissue have shown for the first time how a toxic form of a protein linked to Alzheimer's ...

An increase in physical activity between the ages of 45 and 65 could help prevent Alzheimer's disease, while inactivity may ...